These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 27766216)

  • 21. Nanotechnology-based drug delivery for the treatment of CNS disorders.
    Mittal KR; Pharasi N; Sarna B; Singh M; Rachana ; Haider S; Singh SK; Dua K; Jha SK; Dey A; Ojha S; Mani S; Jha NK
    Transl Neurosci; 2022 Jan; 13(1):527-546. PubMed ID: 36741545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles.
    Psimadas D; Tsotakos T; Fragogeorgi E; Loudos G
    Curr Med Chem; 2015; 22(37):4257-70. PubMed ID: 26511467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic nanoplatforms and delivery strategies for neurological disorders.
    Kang YJ; Cutler EG; Cho H
    Nano Converg; 2018 Nov; 5(1):35. PubMed ID: 30499047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using nanotechnology to design potential therapies for CNS regeneration.
    Ellis-Behnke RG; Teather LA; Schneider GE; So KF
    Curr Pharm Des; 2007; 13(24):2519-28. PubMed ID: 17692020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticles and nanoformulated drugs as promising delivery system in treatment of microbial-induced CNS infection: a systematic review of literature.
    Lashkari A; Ranjbar R
    J Neurovirol; 2021 Aug; 27(4):542-549. PubMed ID: 34227045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art.
    Wang M; Qu Y; Hu D; Niu T; Qian Z
    J Biomed Nanotechnol; 2021 Aug; 17(8):1459-1485. PubMed ID: 34544527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging Use of Nanotechnology in the Treatment of Neurological Disorders.
    Chhabra R; Tosi G; Grabrucker AM
    Curr Pharm Des; 2015; 21(22):3111-30. PubMed ID: 26027574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs.
    Naqvi S; Panghal A; Flora SJS
    Front Neurosci; 2020; 14():494. PubMed ID: 32581676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Theranostical application of nanomedicine for treating central nervous system disorders.
    Ran W; Xue X
    Sci China Life Sci; 2018 Apr; 61(4):392-399. PubMed ID: 29675554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases.
    Luo M; Lee LKC; Peng B; Choi CHJ; Tong WY; Voelcker NH
    Adv Sci (Weinh); 2022 Sep; 9(26):e2201740. PubMed ID: 35851766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Envisioning the Future of Nanomedicines in Management and Treatment of Neurological Disorders.
    Kumar S; Singh P; Sharma S; Pottoo FH; Ali J; Baboota S
    Comb Chem High Throughput Screen; 2021; 24(10):1544-1556. PubMed ID: 33334281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New perspectives of nanoneuroprotection, nanoneuropharmacology and nanoneurotoxicity: modulatory role of amino acid neurotransmitters, stress, trauma, and co-morbidity factors in nanomedicine.
    Sharma HS; Sharma A
    Amino Acids; 2013 Nov; 45(5):1055-71. PubMed ID: 24022705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Covalent nano delivery systems for selective imaging and treatment of brain tumors.
    Ljubimova JY; Sun T; Mashouf L; Ljubimov AV; Israel LL; Ljubimov VA; Falahatian V; Holler E
    Adv Drug Deliv Rev; 2017 Apr; 113():177-200. PubMed ID: 28606739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders.
    Sharma A; Manchanda R; Pottoo FH; Ashraf GM
    Curr Drug Metab; 2021; 22(4):251-262. PubMed ID: 33234099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders.
    Neganova ME; Aleksandrova YR; Sukocheva OA; Klochkov SG
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):805-833. PubMed ID: 35779712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of nanomedicines in delivery of anti-acetylcholinesterase compounds to the brain in Alzheimer's disease.
    Ahmad MZ; Ahmad J; Amin S; Rahman M; Anwar M; Mallick N; Ahmad FJ; Rahman Z; Kamal MA; Akhter S
    CNS Neurol Disord Drug Targets; 2014; 13(8):1315-24. PubMed ID: 25345516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanotechnologies: a strategy to overcome blood-brain barrier.
    De Rosa G; Salzano G; Caraglia M; Abbruzzese A
    Curr Drug Metab; 2012 Jan; 13(1):61-9. PubMed ID: 22292810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.